Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 22.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,421 shares of the company's stock after selling 8,703 shares during the period. Squarepoint Ops LLC owned about 0.10% of Medpace worth $10,107,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of MEDP. Barclays PLC grew its holdings in Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after acquiring an additional 8,275 shares in the last quarter. Atomi Financial Group Inc. bought a new position in shares of Medpace during the fourth quarter valued at approximately $354,000. Nisa Investment Advisors LLC raised its stake in Medpace by 6.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 701 shares of the company's stock worth $233,000 after buying an additional 45 shares in the last quarter. SG Americas Securities LLC raised its stake in Medpace by 967.4% in the fourth quarter. SG Americas Securities LLC now owns 24,593 shares of the company's stock worth $8,171,000 after buying an additional 22,289 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in Medpace by 562.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 54,761 shares of the company's stock worth $18,193,000 after buying an additional 46,493 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MEDP shares. William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and reduced their target price for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Robert W. Baird reduced their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Finally, Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of "Hold" and an average price target of $349.30.

Medpace Trading Up 1.3%

Shares of NASDAQ MEDP traded up $3.70 during midday trading on Tuesday, reaching $298.59. The company had a trading volume of 195,018 shares, compared to its average volume of 353,820. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The business's 50-day simple moving average is $301.18 and its 200 day simple moving average is $326.12. The stock has a market cap of $8.58 billion, a P/E ratio of 23.64, a P/E/G ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the prior year, the firm earned $3.20 EPS. Analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 20.30% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.